Organon &

Organon & Enterprise Value

The Enterprise Value (EV) of Organon & (OGN) as of Oct 16, 2026 is 10.03 B USD. In the previous year, Enterprise Value (EV) was 10.13 B USD — a change of -0.94% (lower).

Enterprise Value

10.03 BUSD

YoY

-0.94%

Last updated:

Enterprise Value (EV) of Organon & is 2025 10.03 B USD. Enterprise Value (EV) of Organon & was 2024 10.13 B USD. It decreases by -0.94% lower compared to the previous year.

The Organon & Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
1.71 B USD
Jan 1, 2019
1.67 B USD
Jan 1, 2020
3.25 B USD
Jan 1, 2021
10.32 B USD
Jan 1, 2022
10.13 B USD
Jan 1, 2023
9.99 B USD
Jan 1, 2024
10.13 B USD
Jan 1, 2025
10.03 B USD
The Organon & Enterprise Value history
YEAREnterprise ValueYoY
10.03 BUSD-0.94%
10.13 BUSD+1.38%
9.99 BUSD-1.38%
10.13 BUSD-1.84%
10.32 BUSD+217.65%
3.25 BUSD+94.24%
1.67 BUSD-2.28%
1.71 BUSD-10.93%
1.92 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co., trading under the ticker symbol OGN and identified by ISIN US68622V1061, stands as a prominent entity within the global healthcare sector, specifically categorized under the pharmaceuticals industry. Headquartered in Jersey City, New Jersey, the United States, the company operates as a science-based global pharmaceutical organization dedicated to developing and delivering innovative health solutions. Since its initial public offering on May 14, 2021, Organon has established itself as a significant player in the market, employing approximately 10,000 full-time staff members who contribute to its extensive research, development, and commercialization efforts. The firm’s strategic focus is centered on a robust portfolio of prescription therapies and medical devices, primarily targeting three key therapeutic areas: women’s health, biosimilars, and established brands. In the realm of women’s health, Organon offers a diverse array of contraception and fertility products. Notable brands within this segment include Nexplanon, Implanon NXT, and NuvaRing, which address various contraceptive needs, alongside fertility treatments such as Follistim AQ and Elonva. These products are designed to provide comprehensive care for patients seeking reproductive health solutions. The company’s biosimilars portfolio is equally substantial, spanning critical treatments in immunology and oncology. This segment reflects Organon’s commitment to providing high-quality, accessible alternatives to biologic medicines, thereby supporting broader patient access to essential therapies. Additionally, the established brands division encompasses a wide range of products in cardiovascular, respiratory, dermatology, and non-opioid pain management. These legacy brands continue to serve a global patient base, ensuring continuity of care for chronic and acute conditions. Organon distributes its products through a multifaceted channel strategy, engaging with drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers. This includes partnerships with health maintenance organizations and pharmacy benefit managers, ensuring that its innovative solutions reach healthcare institutions and individual patients efficiently. By leveraging its scientific expertise and extensive distribution network, Organon & Co. aims to improve health outcomes worldwide, maintaining its position as a vital contributor to the global pharmaceutical landscape. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

Enterprise Value (EV) of Organon & is 10.03 B USD in 2025.

Enterprise Value (EV) of Organon & changed from 10.13 B USD to 10.03 B USD, representing a -0.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Organon & since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Organon & with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Organon &

All Key Metrics — Organon &